EXTX Stock Overview
A clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
EXACT Therapeutics AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 3.72 |
| 52 Week High | NOK 12.00 |
| 52 Week Low | NOK 3.34 |
| Beta | 0.13 |
| 1 Month Change | -34.74% |
| 3 Month Change | -25.60% |
| 1 Year Change | -69.00% |
| 3 Year Change | -77.59% |
| 5 Year Change | n/a |
| Change since IPO | -88.31% |
Recent News & Updates
Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation
Aug 09
Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?
Apr 20Recent updates
Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation
Aug 09Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?
Apr 20We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth
Sep 07We're Hopeful That EXACT Therapeutics (OB:EXTX) Will Use Its Cash Wisely
May 06Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation
Dec 30Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In Growth
Sep 15EXACT Therapeutics (OB:EXTX) Is In A Good Position To Deliver On Growth Plans
Jan 31We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth
Aug 21We're Not Very Worried About EXACT Therapeutics' (OB:EXTX) Cash Burn Rate
May 21Shareholder Returns
| EXTX | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | 3.3% | -3.9% | -2.8% |
| 1Y | -69.0% | -73.8% | -0.8% |
Return vs Industry: EXTX exceeded the Norwegian Biotechs industry which returned -73.8% over the past year.
Return vs Market: EXTX underperformed the Norwegian Market which returned -0.8% over the past year.
Price Volatility
| EXTX volatility | |
|---|---|
| EXTX Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 14.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in NO Market | 10.9% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: EXTX's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: EXTX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 12 | Per Walday | exact-tx.com |
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. The company’s ACT platform is under Phase I clinical trial for treatment of liver metastases; and pre-clinical studies for pancreatic, glioblastoma, and immunotherapy diseases, as well as CNS diseases and gene therapy.
EXACT Therapeutics AS Fundamentals Summary
| EXTX fundamental statistics | |
|---|---|
| Market cap | NOK 119.34m |
| Earnings (TTM) | -NOK 54.84m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.2x
P/E RatioIs EXTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXTX income statement (TTM) | |
|---|---|
| Revenue | NOK 0 |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 0 |
| Other Expenses | NOK 54.84m |
| Earnings | -NOK 54.84m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.71 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did EXTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:43 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
EXACT Therapeutics AS is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|